Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen | サターラ

Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen

関連コンテンツ

Behind the Science: A Conversation with Katrina Hui

How the US FDA MIDD paired pilot program helps sponsors

Behind the Science: A Conversation with Lamia Sid-Otmane

Driving Innovation in Pharmacometrics: An Interview with Wynand Smythe, Associate Director at Certara

Powered by Translations.com GlobalLink Web Software